|Mr. Stijn Van Rompay||Co-Founder & CEO||N/A||N/A||N/A|
|Mr. Thomas Jacobsen||Co-Founder & Exec. Director||N/A||N/A||N/A|
|Mr. Patrick Jeanmart||Chief Financial Officer||N/A||N/A||1972|
|Dr. Dietmar Aichhorn Ph.D.||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Marieke Vermeersch||VP Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Koenraad Van Der Elst||Chief Legal Officer||N/A||N/A||1962|
|Mr. Maurizio Passanisi||Chief Clinical Officer||N/A||N/A||N/A|
|Mr. Ed Maloney||Chief Bus. Devel. Officer||N/A||N/A||N/A|
Hyloris Pharmaceuticals SA manufactures pharmaceutical products. The company offers cardiovascular products for atrial fibrillation, congestive heart failure, and coronary heart disease; intravenous ready-to-use and oral liquid formulations; and topical gel and cream products. Hyloris Pharmaceuticals SA was founded in 2013 and is based in Liege, Belgium.
Hyloris Pharmaceuticals SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.